The Food and Drug Administration (FDA) announced a new proposal Monday for flexible drug approval pathway treatments addressing ultrarare diseases. The FDA unveiled draft guidance on a proposed regulatory pathway for individualized therapies, treatments for rare conditions that affect a very small population, with the proposal specifically focusing on genome editing and RNA-based therapies. The…
